Positive Interim Data from Trial for BonyPid Antibiotic Eluting Bone Substitute

Interim results from study of BonyPid®-1000 in the treatment of open tibial fractures indicate that the bone substitute met performance and safety endpoints in first patients at 6 months.

The 64-patient trial is a randomized, single-blind controlled study of BonyPid-1000 doxycycline-eluting synthetic bone substitute + standard of care (SOC)...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us